Skip to content

Bayer completes voluntary takeover offer for Algeta

Bayer holds 98.2 % of Algeta shares after closing / Compulsory acquisition process planned in the coming days

Leverkusen, March 6, 2014 – The Bayer Group has completed the voluntary takeover offer for Norwegian pharmaceutical company Algeta ASA, Oslo. Payment of the offer price has been made to Algeta’s shareholders who accepted the takeover offer and, at the same time, the 43,131,641 tendered shares have been transferred to Bayer. As a result, Bayer now holds 98.2 % of the shares and voting rights in Algeta.

Bayer intends to initiate a compulsory acquisition process in order to acquire the remaining shares of minority shareholders in Algeta in the coming days. Bayer is offering NOK 362 per share, equal to the offer price in Bayer’s voluntary takeover offer. In addition, Bayer intends to file for delisting of the Algeta shares from the Oslo Stock Exchange (OSE).

Bayer: Science For A Better Life

Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2013, the Group employed 113,200 people and had sales of EUR 40.2 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 3.2 billion. For more information, go to

Find more information at and

Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those described in Bayer’s public reports, which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Source: Bayer